Lung Cancer Advances in Management Ronald B. Natale, M.D. and Martin J. Edelman, M.D. Describe the role of epidermal growth factor receptor (EGFR) in cancer pathophysiology.Explain the relationship between tyrosine kinase inhibitors (TKIs) and EGFR mutations.Select appropriate candidates (from among patients with non-small cell lung cancer) for therapy with TKIs.Evaluate the appropriateness of employing stereotactic body radiation therapy within one's institution and for individual patients.Ensure that patients undergoing treatment for lung cancer receive effective supportive care.CME Qualifies for a maximum 2 AMA PRA Category 1 Credits ™
Cancer of the Head and Neck Scott M. Lippman, M.D. and Arlene A. Forastiere, M.D. Recognize the importance of human papilloma virus (HPV) infection in the incidence of head and neck cancers.Predict outcomes of treatment of head and neck cancer based on HPV positivity.Prescribe treatment for head and neck cancers using a risk-based approach.Describe current challenges in the treatment of laryngeal and hypopharyngeal cancer.Summarize the findings of recent studies comparing induction chemotherapy followed by radiation therapy with concomitant chemoradiotherapy in the treatment of laryngeal and hypopharyngeal cancer.CME Qualifies for a maximum 2 AMA PRA Category 1 Credits ™
Prostate Cancer: An Oncologist's Perspective David I. Quinn, M.B.B.S., Ph.D. and Richard G. Stock, M.D. Describe the quality of the evidence supporting different types of therapy used to treat prostate cancer. Reduce the risk for fractures in men undergoing treatment for prostate cancer.Discuss new approaches to treatment for prostate cancer, including immunotherapy.Assess the evidence supporting better cancer control rates with higher doses of radiation. Evaluate the efficacy of neoadjuvant hormonal therapy for patients with prostate cancer receiving radiation therapy.CME Qualifies for a maximum 2 AMA PRA Category 1 Credits ™
Advances in Profiling and Treating Breast Cancer Kathy S. Albain, M.D. and Christy A. Russell, M.D. Recognize the advantages and disadvantages of multi-gene assays in predicting sensitivity to chemotherapy and prognosis of breast cancer.Identify appropriate candidates for chemotherapy based on hormone receptor status and prognostic signatures.Consider the influence of patient age and previous treatment history when making treatment recommendations for breast cancer.Discuss the use of biologic agents in the treatment of breast cancer.Assess the cardiac and gastrointestinal toxicities of experimental drug therapies for adjuvant and metastatic breast cancer.CME Qualifies for a maximum 2 AMA PRA Category 1 Credits ™
Controversies in the Prognosis and Treatment of Lymphoma Leo I. Gordon, M.D.,Brad S. Kahl, M.D. and Philippe Solal Celigny, M.D., Ph.D. Assess the efficacy of fludarabine and other purine analogues in the treatment of chronic lymphocytic leukemia and indolent lymphomas.Determine whether autologous stem cell transplantation is appropriate therapy for diffuse large B cell lymphomas in first remission. Discuss the role of rituximab in the treatment of high-risk B cell lymphoma.Utilize the Follicular Lymphoma International Prognostic Indicators (FLIPI) 1 and 2 in the prognosis and management of follicular lymphoma.Recognize the prognostic influence of the microenvironment in follicular lymphoma.CME Qualifies for a maximum 2 AMA PRA Category 1 Credits ™
Supportive Oncology Lowell B. Anthony, M.D. and Charles L. Loprinzi, M.D. Recognize the role of new and experimental therapies for treating neuroendocrine tumors (NETs).Utilize long-acting somatostatin analogues (SA) in treating NETs.Assess the efficacy of the multireceptor ligand SA pasireotide in treating metastatic NETs.Determine which therapies are effective in the treatment of established chemotherapy-induced peripheral neuropathy (CIPN).Discuss current research on therapies for preventing CIPN.CME Qualifies for a maximum 2 AMA PRA Category 1 Credits ™
Urologic Perspectives in Prostate Oncology David G. Bostwick, M.D.,E. David Crawford, M.D. and James Eastham, M.D. Recognize the role of markers in the diagnosis of PC. Evaluate a marker's potential reliability based on research results.Assess the utility of screening for PC, based on the results of the Prostate, Lung, Colorectal, and Ovarian (PLCO) trial.Cite the difficulties associated with using prostate-specific antigen in screening for PC.Determine which patients are appropriate candidates for chemoprevention of prostate cancer.CME Qualifies for a maximum 2 AMA PRA Category 1 Credits ™
Critical Issues and Controversies William T. Stephenson, M.D. and Leslie L. Robison, Ph.D. Recognize emergencies that commonly occur in cancer patients.Utilize appropriate treatments for patients with brain metastases, spinal cord metastases, and hypercalcemia of malignancy.Determine which antibiotics are most effective in treating neutropenic fever.Discuss the influence of genetics on the development of childhood cancers.Identify environmental factors associated with increased risk for childhood cancers.CME Qualifies for a maximum 2 AMA PRA Category 1 Credits ™
Prevention and Immunotherapy Michael S. Sabel, M.D. Recognize the limited efficacy of current immuno-therapies in treating advanced melanoma.Assess the potential of newer immunotherapies for melanoma. Identify dietary interventions that may help prevent cancer and cancer recurrence.Recognize the adverse effects of obesity on the development and treatment of cancer.Apply results of research to counseling of cancer patients about diet and lifestyle changes.CME Qualifies for a maximum 2 AMA PRA Category 1 Credits ™
Pancreatic Cancer Selwyn M. Vickers, M.D.,Waddah B. Al Refaie, M.D. and J.Shawn Mallery, M.D. Utilize a multidisciplinary approach for diagnosis and treatment of patients with PC. Discuss the roles, advantages, and limitations of neoadjuvant and adjuvant chemotherapies in treatment of PC.Recognize the limitations of current research in adjuvant and neoadjuvant treatment of PC.Choose appropriate candidates for resection of PC.Diagnose and stage PC via endoscopic ultrasonography.CME Qualifies for a maximum 2 AMA PRA Category 1 Credits ™
Possible Additional Course Available
If you have taken the current course listed here or if you need additional Oncology credits, please call 800-446-5599 and ask about new courses in stock that are not listed on the website.
Testimonials
"I have always been pleased with your continuing medical education seminars in Oncology. I appreciate having the ability to schedule my CE seminars for a time and location best suited and convenient to me. The overall service I receive, the quality of the educational courses, your staff are wonderful." Beth, MD, Los Angeles, CA
"I have taken ASI's Oncology seminars for years. You have an excellent service and staff!" Paul,MD,Houston, TX
"Thanks to ASI, obtaining my Oncology CE could not be easier or more of a pleasure!" Luis,MD,Coral Gables
